New Ray Medicine International Holding (HKG:6108) recorded a loss attributable to owners of HK$4.09 million for the six months ended June 30, narrower than HK$13.4 million logged for the corresponding period last year, a Tuesday filing with the Hong Kong Exchange said.
Loss per share stood at HK$0.0024 for the reporting period, compared to HK$0.0080 recorded for the year-ago period.
The investment and pharmaceutical company's revenue for the first half of this year was HK$16.7 million, 46.1% lower than HK$31.0 million booked a year ago. The company attributed the decrease in revenue to a decrease in demand for its products in the market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。